Study by Karolinska Institutet finds SGLT-2 inhibitors, like Empagliflozin, may improve stroke recovery in diabetic patients.
Study by Karolinska Institutet suggests SGLT-2 inhibitors, commonly used to treat type 2 diabetes, could improve stroke recovery outcomes for diabetic patients. The research, funded by several organizations, found that Empagliflozin promotes post-stroke functional recovery in diabetic mice. Researchers plan to further investigate the association between diabetic treatments and stroke outcomes in clinical studies.
March 01, 2024
3 Articles